Nobivac Myxo-RHD


live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 18/08/2016

Authorisation details

Product details
Nobivac Myxo-RHD
Agency product number
Active substance
live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009
International non-proprietary name (INN) or common name
live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer

Product information

05/08/2016 Nobivac Myxo-RHD - EMEA/V/C/002004 - IAIN/0006


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

For active immunisation of rabbits from five weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease.

Onset of immunity: 3 weeks.

Duration of immunity: 1 year.

Assessment history

How useful was this page?

Add your rating